New perspective on the natural course of chronic HBV infection

Abstract

Chronic hepatitis B virus (HBV) infection is a significant threat to public health and an enormous burden on society. Mechanisms responsible for chronic HBV infection remain poorly understood. A better understanding of the natural course of chronic HBV infection may shed new light on the mechanisms underlying this disease and help in designing new antiviral strategies. Natural course of chronic HBV infection is conventionally viewed as an uninterrupted process that is usually marked by HBV e antigen (HBeAg) seroconversion or characterized by different phases associated with assumed host responses to HBV infection. However, none of these descriptions captures or highlights the core events that determine the natural course of chronic HBV infection. In this review, we briefly present the current knowledge on this subject and explain the significance and implication of events that occur during infection. A pre-core mutant becomes predominant in the viral population following elimination of the wild-type virus in duck hepatitis B virus-chronically infected animals. The coupled events in which first there is viral clearance that clears wild-type virus and then there is the reinfection of wild-type virus cleared livers with mutant virus are highly relevant to understanding of the natural course of chronic HBV infection under both treated and untreated conditions. In our new perspective, a general natural course of chronic HBV infection comprises cycles of viral clearance and reinfection, and such cycles prolong the chronic HBV infection course. Reviewing published data on the natural course of chronic HBV infection can reduce the possibility of missing important points in the initial data interpretation.

Keywords

hepatitis B virus / chronic HBV infection / natural course / hepatitis B / seroconversion

References

[1] LavanchyD.Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol2005; 34(Suppl 1): S1–3

[2] FrancoE, BagnatoB, MarinoMG, MeleleoC, SerinoL, ZarattiL. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol2012; 4(3): 74–80

[3] HoofnagleJH. Hepatitis B-preventable and now treatable. N Engl J Med2006; 354(10): 1074–1076

[4] DienstagJL. Hepatitis B virus infection. N Engl J Med2008; 359(14): 1486–1500

[5] GhanyM, LiangTJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology2007; 132(4): 1574–1585

[6] GhanyMG, DooEC. Antiviral resistance and hepatitis B therapy. Hepatology2009; 49(S5): S174–S184

[7] KwonH, LokAS. Hepatitis B therapy. Nature reviews. Gastroenterol Hepatol2011; 8: 275–284

[8] GishRG, LokAS, ChangTT, de ManRA, GadanoA, SollanoJ, HanKH, ChaoYC, LeeSD, HarrisM, YangJ, ColonnoR, Brett-SmithH. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology2007; 133(5): 1437–1444

[9] LaiCL, ShouvalD, LokAS, ChangTT, CheinquerH, GoodmanZ, DeHertoghD, WilberR, ZinkRC, CrossA, ColonnoR, FernandesL; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med2006; 354(10): 1011–1020

[10] KitrinosKM, CorsaA, LiuY, FlahertyJ, Snow-LampartA, MarcellinP, Borroto-EsodaK, MillerMD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology2014; 59(2): 434–442

[11] YokosukaO, TakaguchiK, FujiokaS, ShindoM, ChayamaK, KobashiH, HayashiN, SatoC, KiyosawaK, TanikawaK, IshikawaH, MasakiN, SeriuT, OmataM. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol2010; 52(6): 791–799

[12] WooG, TomlinsonG, NishikawaY, KowgierM, ShermanM, WongDK, PhamB, UngarWJ, EinarsonTR, HeathcoteEJ, KrahnM. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology2010; 139(4): 1218–1229, 1229.e5

[13] HadziyannisSJ, PapatheodoridisGV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis2006; 26(2): 130–141

[14] HadziyannisSJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol2011; 55(1): 183–191

[15] FernsRB, NaoumovNV, GilsonRJ, TedderRS. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss. J Clin Virol2007; 39: 199–204

[16] BrunettoMR, GiarinMM, OliveriF, ChiabergeE, BaldiM, AlfaranoA, SerraA, SaraccoG, VermeG, WillH. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA1991; 88(10): 4186–4190

[17] BrunettoMR, StemlerM, BoninoF, SchodelF, OliveriF, RizzettoM, VermeG, WillH. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol1990; 10(2): 258–261

[18] OkamotoH, YotsumotoS, AkahaneY, YamanakaT, MiyazakiY, SugaiY, TsudaF, TanakaT, MiyakawaY, MayumiM. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol1990; 64(3): 1298–1303

[19] OkamotoH, TsudaF, AkahaneY, SugaiY, YoshibaM, MoriyamaK, TanakaT, MiyakawaY, MayumiM. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol1994; 68(12): 8102–8110

[20] SeoY, YoonS, NakajiM, YanoY, NaganoH, NinomiyaT, HayashiY, KasugaM. Hepatitis B virus DNA in anti-HBe-positive asymptomatic carriers. Intervirology2003; 46(1): 43–49

[21] KobayashiS, IdeT, SataM. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol2001; 34(4): 584–586

[22] AndoT, SugiyamaK, GotoK, MiyakeY, LiR, KawabeY, WadaY. Age at time of hepatitis Be antibody seroconversion in childhood chronic hepatitis B infection and mutant viral strain detection rates. J Pediatr Gastroenterol Nutr1999; 29(5): 583–587

[23] YamamotoK, HorikitaM, TsudaF, ItohK, AkahaneY, YotsumotoS, OkamotoH, MiyakawaY, MayumiM. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol1994; 68(4): 2671–2676

[24] ShinjiT, KoideN, HanafusaT, HadaH, OkaT, TakayamaN, ShirahaH, NakamuraM, UjikeK, YumotoY, TsujiT. Point mutations in the S and pre-S2 genes observed in two hepatitis B virus carriers positive for antibody to hepatitis B surface antigen. Hepatogastroenterology1998; 45(20): 500–502

[25] FujiwaraK, YokosukaO, EhataT, ChuangWL, ImazekiF, SaishoH, OmataM. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. Dig Dis Sci1998; 43(2): 368–376

[26] KnöllA, RohrhoferA, KochanowskiB, WurmEM, JilgW. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol1999; 59(1): 14–18

[27] Ruiz-TachiquínME, Valdez-SalazarHA, Juárez-BarretoV, Dehesa-ViolanteM, TorresJ, Muñoz-HernándezO, Alvarez-MuñozMT. Molecular analysis of hepatitis B virus “a” determinant in asymptomatic and symptomatic Mexican carriers. Virol J2007; 4(1): 6

[28] LokAS, AkarcaU, GreeneS. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA1994; 91(9): 4077–4081

[29] CarmanWF, JacynaMR, HadziyannisS, KarayiannisP, McGarveyMJ, MakrisA, ThomasHC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet1989; 334(8663): 588–591

[30] LindhM, FurutaY, VahlneA, NorkransG, HoralP. Emergence of precore TAG mutation during hepatitis B e seroconversion and its dependence on pregenomic base pairing between nucleotides 1858 of 1896. J Infect Dis1995; 172(5): 1343–1347

[31] BrunettoMR, GiarinM, SaraccoG, OliveriF, CalvoP, CapraG, RandoneA, AbateML, ManziniP, CapalboM, . Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology1993; 105(3): 845–850

[32] RaimondoG, StemlerM, SchneiderR, WildnerG, SquadritoG, WillH. Latency and reactivation of a precore mutant hepatitis B virus in a chronically infected patient. J Hepatol1990; 11(3): 374–380

[33] SantantonioT, JungMC, MiskaS, PastoreG, PapeGR, WillH. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology1991; 183(2): 840–844

[34] ChuCJ, KeeffeEB, HanSH, PerrilloRP, MinAD, Soldevila-PicoC, CareyW, BrownRS Jr, LuketicVA, TerraultN, LokAS. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology2003; 125(2): 444–451

[35] ManzinA, PaolucciS, LamperticoP, MenzoS, RumiMG, ColomboM, ClementiM. Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. Res Virol1993; 144(4): 303–306

[36] TakedaK, AkahaneY, SuzukiH, OkamotoH, TsudaF, MiyakawaY, MayumiM. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology1990; 12(6): 1284–1289

[37] LarasA, KoskinasJ, AvgidisK, HadziyannisSJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat1998; 5(4): 241–248

[38] KarasawaT, ShirasawaT, OkawaY, KuramotoA, ShimadaN, AizawaY, ZeniyaM, TodaG. Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers. J Gastroenterol1997; 32(5): 611–622

[39] LinCL, LiaoLY, LiuCJ, ChenPJ, LaiMY, KaoJH, ChenDS. Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol2002; 37(4): 283–287

[40] FunkML, RosenbergDM, LokAS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat2002; 9(1): 52–61

[41] OmataM, EhataT, YokosukaO, HosodaK, OhtoM. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med1991; 324(24): 1699–1704

[42] Tur-KaspaR, KleinA, AharonsonS. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology1992; 16(6): 1338–1342

[43] AritomiT, YatsuhashiH, FujinoT, YamasakiK, InoueO, KogaM, KatoY, YanoM. Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol1998; 13(11): 1125–1132

[44] AlexopoulouA, KarayiannisP, HadziyannisSJ, HouJ, PickeringJ, LuoK, ThomasHC. Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity. J Viral Hepat1996; 3(4): 173–181

[45] EhataT, OmataM, ChuangWL, YokosukaO, ItoY, HosodaK, OhtoM. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest1993; 91(3): 1206–1213

[46] HondaA, YokosukaO, SuzukiK, SaishoH. Detection of mutations in hepatitis B virus enhancer 2/core promoter and X protein regions in patients with fatal hepatitis B virus infection. J Med Virol2000; 62(2): 167–176

[47] InoueK, OgawaO, YamadaM, WatanabeT, OkamotoH, YoshibaM. Possible association of vigorous hepatitis B virus replication with the development of fulminant hepatitis. J Gastroenterol2006; 41(4): 383–387

[48] LiangTJ, HasegawaK, RimonN, WandsJR, Ben-PorathE. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med1991; 324(24): 1705–1709

[49] NagasakiF, UenoY, NiitsumaH, InoueJ, KogureT, FukushimaK, KobayashiK, ShimosegawaT. Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J Med Virol2008; 80(6): 967–973

[50] SainokamiS, AbeK, SatoA, EndoR, TakikawaY, SuzukiK, OkamotoH. Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol2007; 42(3): 241–249

[51] YuasaR, TakahashiK, DienBV, BinhNH, MorishitaT, SatoK, YamamotoN, IsomuraS, YoshiokaK, IshikawaT, MishiroS, KakumuS. Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis. J Med Virol2000; 61(1): 23–28

[52] ShirakiK, HamadaM, SugimotoK, ItoT, YamanakaT, WagayamaH, ShimizuA, MakinoY, TakaseK, NakanoT, TamedaY. Detection of precore-mutant hepatitis B virus genome in patients with acute and fulminant hepatitis using mutation site-specific assay (MSSA). Hepatogastroenterology2002; 49(47): 1352–1356

[53] ChuCM, YehCT, ChiuCT, SheenIS, LiawYF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol1996; 34(7): 1815–1818

[54] SantantonioT, JungMC, MiskaS, PastoreG, PapeGR, WillH. High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in southern Italy. J Hepatol1991; 13(Suppl 4): S78–S81

[55] ChanHL, LeungNW, HussainM, WongML, LokAS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology2000; 31(3): 763–768

[56] TongSP, LiJS, VitvitskiL, TrépoC. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology1990; 176(2): 596–603

[57] LiJ, TongS, VitvitskiL, ZoulimF, TrépoC. Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. J Gen Virol1990; 71(9): 1993–1998

[58] YangHC, ChenCL, ShenYC, PengCY, LiuCJ, TsengTC, SuTH, ChuangWL, YuML, DaiCY, LiuCH, ChenPJ, ChenDS, KaoJH. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology2013; 57(3): 934–943

[59] ChenCH, LeeCM, HungCH, HuTH, WangJH, WangJC, LuSN, ChangchienCS. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int2007; 27: 806–815

[60] LiawYF, ChuCM. Hepatitis B virus infection. Lancet2009; 373(9663): 582–592

[61] ZhangYY, SummersJ. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol1999; 73(5): 3616–3622

[62] PultI, AbbottN, ZhangYY, SummersJ. Frequency of spontaneous mutations in an avian hepadnavirus infection. J Virol2001; 75(20): 9623–9632

[63] Werle-LapostolleB, BowdenS, LocarniniS, WursthornK, PetersenJ, LauG, TrepoC, MarcellinP, GoodmanZ, DelaneyWE 4th, XiongS, BrosgartCL, ChenSS, GibbsCS, ZoulimF. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology2004; 126(7): 1750–1758

[64] LokAS, AkarcaUS, GreeneS. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology1995; 21(1): 19–24

[65] NieH, EvansAA, LondonWT, BlockTM, RenXD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol2012; 56(4): 795–802

[66] ZhuY, YamamotoT, CullenJ, SaputelliJ, AldrichCE, MillerDS, LitwinS, FurmanPA, JilbertAR, MasonWS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol2001; 75(1): 311–322

[67] BourneEJ, DienstagJL, LopezVA, SanderTJ, LongletJM, HallJG, KwiatkowskiRW, WrightT, LaiCL, CondreayLD. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat2007; 14(1): 55–63

[68] WursthornK, LutgehetmannM, DandriM, VolzT, BuggischP, ZollnerB, LongerichT, SchirmacherP, MetzlerF, ZankelM, FischerC, CurrieG, BrosgartC, PetersenJ. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology2006; 44(3): 675–684

[69] WongDK, YuenMF, NgaiVW, FungJ, LaiCL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther2006; 11(7): 909–916

[70] TakkenbergB, TerpstraV, ZaaijerH, WeeginkC, DijkgraafM, JansenP, BeldM, ReesinkH. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol2011; 26(10): 1527–1535

[71] LutgehetmannM, VolztT, QuaasA, ZankelM, FischerC, DandriM, PetersenJ. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther2008; 13(1): 57–66

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg